Affordable Access

Access to the full text

Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal–CA1 projection

Authors
  • Li, Peng1
  • Xu, Jin1
  • Gu, Huanhuan1
  • Peng, Hua1
  • Yin, You1
  • Zhuang, Jianhua1
  • 1 Shanghai Changzheng Hospital, Navy Medical University, Shanghai, 200003, China , Shanghai (China)
Type
Published Article
Journal
BMC Neuroscience
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jun 14, 2021
Volume
22
Issue
1
Identifiers
DOI: 10.1186/s12868-021-00647-y
Source
Springer Nature
Keywords
Disciplines
  • Research
License
Green

Abstract

BackgroundMemantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve cognitive functions in animal models of Alzheimer’s disease (AD). Here we treated APP/PS1 AD mice with a therapeutic dose of memantine (20 mg/kg/day) and examined its underlying mechanisms in ameliorating cognitive defects.MethodsUsing behavioral, electrophysiological, optogenetic and morphology approaches to explore how memantine delay the pathogenesis of AD.ResultsMemantine significantly improved the acquisition in Morris water maze (MWM) in APP/PS1 mice without affecting the speed of swimming. Furthermore, memantine enhanced EC to CA1 synaptic neurotransmission and promoted dendritic spine regeneration of EC neurons that projected to CA1.ConclusionsOur study reveals the underlying mechanism of memantine in the treatment of AD mice.

Report this publication

Statistics

Seen <100 times